The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
Danielle M Dunlea, Laura T Fee, Thomas McEnery, Noel G McElvaney, Emer P Reeves Irish Centre for Genetic Lung Disease, Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland Abstract: Alpha-1 antitrypsin (AAT) is the most abundant serine protease inhibitor c...
Guardado en:
Autores principales: | Dunlea DM, Fee LT, McEnery T, McElvaney NG, Reeves EP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f1620ab2eb794c16b3c4e4484422dd48 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
PROINFLAMMATORY CYTOKINE PROFILE IN PATIENTS WITH DIFFERENT ALPHA-1-ANTITRYPSIN PHENOTYPES
por: M. Yu. Pervakova, et al.
Publicado: (2016) -
Construction of an engineered alpha 1-antitrypsin with inhibitory activity based on theoretical studies
por: Sangachini,Elham Dasi, et al.
Publicado: (2012) -
Elevating the expression level of biologically active recombinant human alpha 1-antitrypsin in Pichia pastoris
por: Arjmand,Sareh, et al.
Publicado: (2013) -
Evaluation of Alpha-1 antitrypsin level in the serum of children with idiopathic bronchiectasis
por: Maryam Babaei, et al.
Publicado: (2021) -
Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?
por: Ortiz,Gustavo, et al.
Publicado: (2014)